HUP0301699A3 - Producing imidazolylanilin derivatives with efficient ligand-mediated ullmann coupling of anilines and azoles - Google Patents
Producing imidazolylanilin derivatives with efficient ligand-mediated ullmann coupling of anilines and azolesInfo
- Publication number
- HUP0301699A3 HUP0301699A3 HU0301699A HUP0301699A HUP0301699A3 HU P0301699 A3 HUP0301699 A3 HU P0301699A3 HU 0301699 A HU0301699 A HU 0301699A HU P0301699 A HUP0301699 A HU P0301699A HU P0301699 A3 HUP0301699 A3 HU P0301699A3
- Authority
- HU
- Hungary
- Prior art keywords
- imidazolylanilin
- anilines
- azoles
- derivatives
- producing
- Prior art date
Links
- 238000006887 Ullmann reaction Methods 0.000 title 1
- 150000001448 anilines Chemical class 0.000 title 1
- 150000003851 azoles Chemical class 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- YCAXQAUEKMQYQH-UHFFFAOYSA-N n-phenyl-1h-imidazol-2-amine Chemical class C=1C=CC=CC=1NC1=NC=CN1 YCAXQAUEKMQYQH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Executing Machine-Instructions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22093200P | 2000-07-26 | 2000-07-26 | |
| PCT/US2001/023541 WO2002008199A2 (en) | 2000-07-26 | 2001-07-26 | Efficient ligand-mediated ullmann coupling of anilines and azoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0301699A2 HUP0301699A2 (hu) | 2003-12-29 |
| HUP0301699A3 true HUP0301699A3 (en) | 2004-03-29 |
Family
ID=22825611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301699A HUP0301699A3 (en) | 2000-07-26 | 2001-07-26 | Producing imidazolylanilin derivatives with efficient ligand-mediated ullmann coupling of anilines and azoles |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6541639B2 (hu) |
| EP (1) | EP1307431B1 (hu) |
| JP (1) | JP2004504384A (hu) |
| KR (1) | KR20030060872A (hu) |
| CN (1) | CN1444565A (hu) |
| AT (1) | ATE307804T1 (hu) |
| AU (1) | AU2001280813A1 (hu) |
| BR (1) | BR0112746A (hu) |
| CA (1) | CA2417426A1 (hu) |
| DE (1) | DE60114424T2 (hu) |
| EC (1) | ECSP034453A (hu) |
| ES (1) | ES2251501T3 (hu) |
| HU (1) | HUP0301699A3 (hu) |
| IL (1) | IL153547A0 (hu) |
| IS (1) | IS6695A (hu) |
| MX (1) | MXPA03000686A (hu) |
| NO (1) | NO20030393L (hu) |
| NZ (1) | NZ523271A (hu) |
| PL (1) | PL361233A1 (hu) |
| RU (1) | RU2003103706A (hu) |
| WO (1) | WO2002008199A2 (hu) |
| ZA (1) | ZA200300039B (hu) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2445159C (en) * | 2001-04-24 | 2012-09-11 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| CN101613321A (zh) | 2002-03-05 | 2009-12-30 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
| EP1509502A1 (fr) * | 2002-05-31 | 2005-03-02 | Rhodia Chimie | Procede de formation d une liaison carbone-carbone ou carbone-heteroatome |
| AU2003257062A1 (en) | 2002-08-02 | 2004-02-23 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| WO2004031143A2 (en) * | 2002-10-02 | 2004-04-15 | Bristol-Myers Squibb Company | Novel combination of a factor xa inhibitor and clopidogrel |
| BRPI0410436A (pt) * | 2003-05-20 | 2006-05-30 | Transtech Pharma Inc | antagonistas de rage como agentes para amiloidose reversa e doenças associadas com a mesma |
| EP1768947A1 (en) * | 2004-07-16 | 2007-04-04 | DSMIP Assets B.V. | Process for the preparation of an (hetero) arylamine |
| CN101796051B (zh) | 2007-03-12 | 2013-11-06 | 细胞内治疗公司 | 与取代的杂环稠合的γ-咔啉的合成 |
| WO2011041198A1 (en) | 2009-09-30 | 2011-04-07 | Transtech Pharma, Inc. | Substituted imidazole derivatives for treatment of alzheimers disease |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2893621T3 (es) | 2013-12-03 | 2022-02-09 | Intra Cellular Therapies Inc | Métodos para el tratamiento de los síntomas residuales de la esquizofrenia |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20170012209A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2015171951A1 (en) * | 2014-05-07 | 2015-11-12 | The Regents Of The University Of Colorado, A Body Corporate | 2-(4-aryl-1h-imidazol-1-yl)aniline compounds |
| DK3407888T3 (da) | 2016-01-26 | 2021-04-06 | Intra Cellular Therapies Inc | Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser |
| JP6686168B2 (ja) | 2016-03-25 | 2020-04-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| WO2017172784A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2017172811A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel co-crystals |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
| CN116327770A (zh) | 2017-03-24 | 2023-06-27 | 细胞内治疗公司 | 新组合物和方法 |
| AU2018307480B2 (en) | 2017-07-26 | 2023-11-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN111093665A (zh) | 2017-07-26 | 2020-05-01 | 细胞内治疗公司 | 有机化合物 |
| EP3762368B1 (en) | 2018-03-08 | 2022-01-26 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-y inhibitors |
| JP7483671B2 (ja) | 2018-06-11 | 2024-05-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ－カルボリン類合成 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| KR20210052472A (ko) | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6372658A (ja) | 1986-09-17 | 1988-04-02 | Sumitomo Chem Co Ltd | ニトロジフエニルアミン類の製造方法 |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
-
2001
- 2001-07-25 US US09/912,950 patent/US6541639B2/en not_active Expired - Fee Related
- 2001-07-26 IL IL15354701A patent/IL153547A0/xx unknown
- 2001-07-26 PL PL36123301A patent/PL361233A1/xx not_active Application Discontinuation
- 2001-07-26 KR KR10-2003-7001155A patent/KR20030060872A/ko not_active Application Discontinuation
- 2001-07-26 WO PCT/US2001/023541 patent/WO2002008199A2/en active IP Right Grant
- 2001-07-26 HU HU0301699A patent/HUP0301699A3/hu unknown
- 2001-07-26 CN CN01813378A patent/CN1444565A/zh active Pending
- 2001-07-26 CA CA002417426A patent/CA2417426A1/en not_active Abandoned
- 2001-07-26 RU RU2003103706/04A patent/RU2003103706A/ru not_active Application Discontinuation
- 2001-07-26 ES ES01959231T patent/ES2251501T3/es not_active Expired - Lifetime
- 2001-07-26 AU AU2001280813A patent/AU2001280813A1/en not_active Abandoned
- 2001-07-26 EP EP01959231A patent/EP1307431B1/en not_active Expired - Lifetime
- 2001-07-26 MX MXPA03000686A patent/MXPA03000686A/es unknown
- 2001-07-26 JP JP2002514105A patent/JP2004504384A/ja active Pending
- 2001-07-26 DE DE60114424T patent/DE60114424T2/de not_active Expired - Fee Related
- 2001-07-26 BR BR0112746-2A patent/BR0112746A/pt not_active IP Right Cessation
- 2001-07-26 AT AT01959231T patent/ATE307804T1/de not_active IP Right Cessation
- 2001-07-26 NZ NZ523271A patent/NZ523271A/en unknown
-
2003
- 2003-01-02 ZA ZA200300039A patent/ZA200300039B/en unknown
- 2003-01-22 IS IS6695A patent/IS6695A/is unknown
- 2003-01-24 NO NO20030393A patent/NO20030393L/no not_active Application Discontinuation
- 2003-01-24 EC EC2003004453A patent/ECSP034453A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002008199A2 (en) | 2002-01-31 |
| ECSP034453A (es) | 2003-03-31 |
| NO20030393L (no) | 2003-03-24 |
| DE60114424T2 (de) | 2006-07-27 |
| RU2003103706A (ru) | 2004-08-10 |
| US6541639B2 (en) | 2003-04-01 |
| IS6695A (is) | 2003-01-22 |
| HUP0301699A2 (hu) | 2003-12-29 |
| EP1307431B1 (en) | 2005-10-26 |
| ES2251501T3 (es) | 2006-05-01 |
| IL153547A0 (en) | 2003-07-06 |
| WO2002008199A3 (en) | 2002-06-13 |
| ZA200300039B (en) | 2004-04-02 |
| US20020099225A1 (en) | 2002-07-25 |
| BR0112746A (pt) | 2003-09-09 |
| NO20030393D0 (no) | 2003-01-24 |
| KR20030060872A (ko) | 2003-07-16 |
| MXPA03000686A (es) | 2003-06-06 |
| DE60114424D1 (de) | 2005-12-01 |
| ATE307804T1 (de) | 2005-11-15 |
| CN1444565A (zh) | 2003-09-24 |
| AU2001280813A1 (en) | 2002-02-05 |
| EP1307431A2 (en) | 2003-05-07 |
| PL361233A1 (en) | 2004-10-04 |
| NZ523271A (en) | 2005-01-28 |
| JP2004504384A (ja) | 2004-02-12 |
| CA2417426A1 (en) | 2002-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0301699A3 (en) | Producing imidazolylanilin derivatives with efficient ligand-mediated ullmann coupling of anilines and azoles | |
| HU9904445D0 (en) | Aniline derivatives and process for the preparation of the same | |
| IL154031A0 (en) | Substituted sulfonylaminomethylbenzoic acid derivatives and preparation | |
| IL156737A0 (en) | Substituted amine derivatives and methods of use | |
| HUP0200898A2 (en) | Derivatives of venlafaxine and methods of preparing and using the same | |
| HUP0300527A3 (en) | Pyrrolopyrimidinone derivatives, process of preparation and use | |
| AU2001227751A1 (en) | Thermal joint and method of use | |
| PL339330A1 (en) | Method of obtaining derivatives of quinazoline and novel intermediate compounds | |
| IL149374A0 (en) | New use and novel n-azabicyclo-amide derivatives | |
| HUP0202477A3 (en) | Use of phthalazine derivatives | |
| GB2323285B (en) | Orifice couplings parts therefor and methods of production | |
| HUP0102637A3 (en) | Coupling sleeve and sleeve joint | |
| PL373846A1 (en) | Method of reducing mortality and morbidity associated with critical illnesses | |
| AU2001255199A1 (en) | Ceramide derivatives and method of use | |
| AU4819899A (en) | Coupling half and method of making same | |
| IL152580A0 (en) | Process for the preparation of indole derivatives and intermediates of the process | |
| AU2001260774A1 (en) | Bio-support and preparing method of the same | |
| HK1041200A1 (zh) | 化學化合物及其用途 | |
| AU2001284004A1 (en) | Nitroderivatives of polysaccharides | |
| EP1392317A4 (en) | SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF | |
| AU4708200A (en) | Tow and process of making | |
| HUP0401162A3 (en) | Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives | |
| EP1229913A4 (en) | SUBSTITUTED 1-BENZAZEPINE AND THEIR DERIVATIVES | |
| AU8964201A (en) | Novel aniline derivatives | |
| EP1310503A4 (en) | PROCESS FOR THE PRODUCTION OF HYDRAZINOMONOSACCHARIDE DERIVATIVES AND THEIR USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |